Scheduled Event - Friday 21st June
View Source
Commons - Private Members' Bills - Main Chamber
Brain Tumours Bill 2023-24
MP: Siobhain McDonagh

---

Select Committee

University of Glasgow

CRG0008 - City Region and Growth Deals

Written Evidence Apr. 23 2024

Inquiry: City Region and Growth Deals
Inquiry Status: Closed
Committee: Scottish Affairs Committee (Department: Scotland Office)

Found: driving the development of imaging technology to understand and benefit diseases such as stroke, brain

---

Scheduled Event - Friday 19th April
View Source
Commons - Private Members' Bills - Main Chamber
Brain Tumours Bill 2023-24
MP: Siobhain McDonagh

---

---

---

---

---

Departmental Publication (Transparency)
Home Office

Apr. 12 2024

Source Page: Non-technical summaries granted in 2024
Document: Non-technical summaries: projects granted in 2024, January to March (PDF)

Found: tumours 578 70.

---

Non-Departmental Publication (Guidance and Regulation)
Medicines and Healthcare products Regulatory Agency

Apr. 04 2024

Source Page: International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use Guidelines
Document: Q3D(R2) – Guideline for Elemental Impurities (PDF)

Found: Cadmium was clearly positive for lung tumours in rats; non-significant, non dose dependent in mice;

---

Written Question

Brain: Tumours

Wednesday 3rd April 2024

Asked by: Charles Walker (Conservative - Broxbourne)

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what assessment she has made of the adequacy of the level of NHS funding for brain tumour research compared to research into other cancers; and if she will provide the quantum of NHS research funding into brain tumours for each of the last five financial years.

Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)

The Department invests over £1 billion per year into health research, through the National Institute for Health Research (NIHR), whose research spending for all cancers was £121.8 million in 2022/23. Funding for the delivery of brain cancer studies in the National Health Service cannot be disaggregated from other studies, but to indicate scale, in 2022/23 the NIHR Clinical Research Network supported 61 brain cancer studies and recruited 4,317 participants to these studies.

Over the past five financial years, the NIHR has spent over £11.3 million in funding for brain cancer research. The following table shows the amount of funding awarded for brain cancer research, from 2018/19 to 2022/23:

Financial Year	Funding amount
2018/19	£2.9 million
2019/20	£150,000
2020/21	£2.2 million
2021/22	£5.3 million
2022/23	£750,000
Total	£11.3 million

Note: the amount of funding awarded will differ to actual spend in a given year, as total spending will include that of multi-year awards made in previous years.

The NIHR funds research in response to proposals received from scientists, rather than allocating funding to specific disease areas. It is not usual practice to ring-fence funds for particular topics or conditions. Applications are subject to peer review and judged in open competition, with awards made on the basis of the importance of the topic to patients and health and care services, value for money, and scientific quality.

To increase the quality, diversity, and number of brain cancer research proposals, the NIHR is working with the Tessa Jowell Brain Cancer Mission and the research community, to develop research capacity in the brain cancer community.

---